Cronos Group Inc. Reports Board and Executive Changes
Ticker: CRON · Form: 8-K · Filed: 2025-08-29T00:00:00.000Z
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Cronos Group board shakeup, new director elected, exec comp updated.
AI Summary
Cronos Group Inc. announced on August 29, 2025, a change in its board of directors. Specifically, the company reported the departure of a director and the election of a new director, along with updates to its executive compensation arrangements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership effectiveness.
Key Players & Entities
- Cronos Group Inc. (company) — Registrant
- August 29, 2025 (date) — Date of Report
FAQ
Who is the departing director from Cronos Group Inc.?
The filing does not specify the name of the departing director.
Who is the newly elected director at Cronos Group Inc.?
The filing does not specify the name of the newly elected director.
What specific changes were made to executive compensation arrangements?
The filing indicates that there were updates to compensatory arrangements of certain officers, but the specific details are not provided in this summary.
What is the primary business of Cronos Group Inc.?
Cronos Group Inc. is in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry, SIC code 2833.
When was Cronos Group Inc. formerly known as PharmaCan Capital Corp.?
The company changed its name from PharmaCan Capital Corp. on October 21, 2015.
From the Filing
0001656472-25-000083.txt : 20250829 0001656472-25-000083.hdr.sgml : 20250829 20250829160328 ACCESSION NUMBER: 0001656472-25-000083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250829 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250829 DATE AS OF CHANGE: 20250829 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cronos Group Inc. CENTRAL INDEX KEY: 0001656472 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38403 FILM NUMBER: 251280750 BUSINESS ADDRESS: STREET 1: 4491 CONCESSION RD 12 CITY: STAYNER STATE: A6 ZIP: L0M 1S0 BUSINESS PHONE: (416) 504-0004 MAIL ADDRESS: STREET 1: 6D - 7398 YONGE ST STREET 2: PMB 732 CITY: THORNHILL STATE: A6 ZIP: L4J 8J2 FORMER COMPANY: FORMER CONFORMED NAME: PharmaCan Capital Corp. DATE OF NAME CHANGE: 20151021 8-K 1 cron-20250829.htm 8-K cron-20250829 0001656472 0001656472 2025-08-29 2025-08-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 CRONOS GROUP INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38403 N/A (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 4491 Concession Rd 12 Stayner , Ontario L0M 1S0 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (416) 504-0004 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value CRON The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 29, 2025, Cronos Group Inc. (the “Company”) terminated Lloyd Wilson, the Company’s Vice President, Controller and Principal Accounting Officer, for cause and effective immediately. Mr. Wilson’s termination was not related to the Company’s financial or operating results or internal controls, or to any disagreements or concerns regarding the Company’s financial or reporting practices or internal controls. SIGNATURES Pursuant to the